Fabrication of doxorubicin conjugated methoxy poly(ethylene glycol)-block-poly(ε-caprolactone) nanoparticles and study on their in vitro antitumor activities

Abstract

The purpose of this study was to develop a novel drug-polymer conjugation (mPEG-b-PCL-DOX) and study on its toxicity, bio-safety, and in vitro antitumor activity of mPEG-b-PCL-DOX. The polymer methoxy poly(ethylene glycol)-block-poly(ε-caprolactone) (mPEG-b-PCL) was prepared by ring-opening polymerization. Then, succinic anhydride was reacted with mPEG-b-PCL via esterification reaction to produce mPEG-b-PCL-COOH. Finally, the polymer mPEG-b-PCL-DOX was obtained by conjugating DOX to mPEG-b-PCL-COOH by amidation. The Fourier transform infrared spectroscopy (FTIR) and ¹H nuclear magnetic resonance (¹H NMR) spectra were used to study the structures of obtained polymers. Transmission electron microscope (TEM) and Dynamic laser scattering (DLS) were employed to monitor the morphology and size distribution of mPEG-b-PCL-DOX nanoparticles (NPs). The mPEG-b-PCL-DOX NPs were administrated to KM rats by intraperitoneal injection to study the bio-safety of final NPs. The cell uptake and in vitro anti-tumor activity of final NPs were carried out with HCT116 cells as models. FTIR and ¹H NMR spectra confirmed the obtaining of mPEG-b-PCL-DOX. The fabricated NPs were in round shapes with an average diameter of 300 nm. These NPs did not induce hemolysis and physiological or pathological changes in rats’s organs. Finally, cell teats showed that these NPs could be endocytosed by HCT 116 cells, and they had better anti-tumor effects than free DOX did. Therefore, the mPEG-b-PCL-DOX NPs had a potential application in anti-cancer therapy.

Keywords:

• Bio-safety
• DOX
• anti-tumor
• hemolysis
• pathological sections

Additional information

Funding

This project was supported by scientific research fund of Yancheng Polytechnic College (No. ygy2009).